Epistemic AI
Epistemic AI builds a multi-agent generative AI platform, anchored by a proprietary biomedical Knowledge Graph, that automates strategic intelligence deliverables—competitive landscapes, target product profiles, and conference intelligence—for Top-20 pharmaceutical companies and mid-size biotechs, with expert-validated outputs sold via annual subscriptions or one-off projects.
- Company typePrivate
- Founded2021
- HeadquartersWestport, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Epistemic AI does
Epistemic AI is a knowledge discovery and strategic intelligence platform purpose-built for the life sciences industry. Founded in 2018 and headquartered in Westport, Connecticut, the company serves biopharmaceutical R&D organizations by automating strategic deliverables—competitive landscapes, target product profiles (TPPs), conference intelligence, clinical trial analysis, KOL mapping, and regulatory/RWE intelligence—that traditionally require months of consulting work. Its primary customer segments are Top-20 pharmaceutical companies and mid-size biotechs, with use cases spanning corporate strategy, portfolio planning, competitive intelligence, and medical affairs. The company currently operates with 11-50 employees.
The platform is anchored by the proprietary Epistemic Knowledge Graph, which integrates billions of biomedical entities (drugs, clinical trials, genes, publications, regulatory filings, and patents) from hundreds of trusted sources including the FDA, EMA, ClinicalTrials.gov, PubMed, and global patent databases. On top of this knowledge graph, the company has built EpistemicGPT, a multi-agent generative AI system in which specialized AI agents handle distinct analytical tasks such as clinical trial analysis, competitive landscape mapping, regulatory filing extraction, and publication synthesis. Each agent's reasoning chain is fully traceable, and every output is validated by in-house life science experts before delivery, a human-in-the-loop layer the company positions as regulatory-grade intelligence.
Epistemic AI monetizes through two engagement models: Strategic Automation Projects (one-off, quote-based engagements for individual deliverables) and a Living Platform annual subscription providing ongoing access to automated TPPs, competitive landscapes, conference intelligence, EpistemicGPT, and the Knowledge Graph with dedicated scientific services support. The company runs an enterprise sales-led motion with a dedicated commercial team including a Chief Commercial Officer, VP Commercial and Product Strategy, VP Sales, and Sr. Director of Sales. To date, Epistemic AI has raised roughly $16 million in disclosed funding across multiple rounds, including a $4 million strategic minority investment from ClearView Healthcare Partners in January 2025 and a prior round in April 2024 of approximately $6.4 million.
Epistemic AI firmographics
Firmographics- Name
- Epistemic AI
- Legal name
- Epistemic AI, Inc.
- Website
- https://epistemic.ai
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Epistemic AI builds a multi-agent generative AI platform, anchored by a proprietary biomedical Knowledge Graph, that automates strategic intelligence deliverables—competitive landscapes, target product profiles, and conference intelligence—for Top-20 pharmaceutical companies and mid-size biotechs, with expert-validated outputs sold via annual subscriptions or one-off projects.
- Ownership category
- akta.pro rank
Epistemic AI industry classification
Industry- Product category
- Life Sciences Strategic Intelligence Software
- NAICS
- Software Publishers (51321)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industry
- End-to-End Enterprise AI Platforms (MLOps & Model Lifecycle Management) (HDAEANAA)
Keywords
Where Epistemic AI is headquartered
LocationHeadquarters
- HQ city
- Westport
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Epistemic AI business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Living Platform Subscription: Annual platform subscription providing ongoing access to automated TPPs, competitive landscapes, conference intelligence, EpistemicGPT, the Epistemic Knowledge Graph, and dedicated scientific services support.
- Strategic Automation Projects: One-off project engagements for individual competitive landscapes, target product profiles, or conference intelligence reports. AI-generated and validated by life science experts. Ideal for proof-of-concept or single-indication needs.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Strategic Automation Projects for focused, individual deliverables |
| Subscription | Annual | Living Platform annual subscription for portfolio-wide automation |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Epistemic AI product offering
Product offeringCore offering
Epistemic AI sells a Strategic Intelligence Platform for Life Sciences built around EpistemicGPT, a multi-agent generative AI system grounded in a proprietary Epistemic Knowledge Graph of billions of biomedical entities. The platform automates competitive landscapes, target product profiles (TPPs), conference intelligence, clinical trials analysis, KOL mapping, drug and omics mapping for biopharma corporate strategy, portfolio planning, and medical affairs teams, with outputs validated by in-house life science experts.
Product overview
Epistemic AI is a Strategic Intelligence Platform for Life Sciences that automates strategic deliverables for biopharma companies. The platform uses a modular architecture built around the Epistemic Knowledge Graph—a proprietary knowledge graph containing billions of biomedical entities (drugs, trials, companies, genes, publications, regulatory filings). Core products include EpistemicGPT (multi-agent AI system for answering strategic questions), Knowledge Map (foundational data layer), and specialized modules for Competitive Intelligence, Target Product Profiles (TPP), Conference Intelligence, Clinical Trials Intelligence, KOL Mapping, Drug Map, and Omics Map. Deliverables are AI-generated and validated by in-house life science experts. Service offerings include Strategic Automation Projects (individual deliverables) and the Living Platform (annual subscription with full platform access).
Differentiator
Problem solved
Functional benefit
Products and services
- EpistemicGPT Multi-agent generative AI system built to automate life science strategy. Users ask strategic questions and receive structured, validated answers backed by the Epistemic Knowledge Graph, with outputs reviewed by in-house life science experts before delivery.
- Living Platform Subscription Annual platform subscription providing ongoing access to automated target product profiles, competitive landscapes, conference intelligence, EpistemicGPT, the Epistemic Knowledge Graph, and dedicated scientific services support.
- Strategic Automation Projects Project-based engagements delivering individual competitive landscapes, target product profiles, or conference intelligence reports. AI-generated and validated by in-house life science experts, suited to proof-of-concept or single-indication needs.
Quantifiable outcome
- Competitive landscapes automatically generated in days, not months
- +2 more outcomes
Companies that use Epistemic AI
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Epistemic AI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature5 records
Epistemic AI partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights6 records
Epistemic AI competitors and assessment
Company assessmentDirect peers
- Causaly: Causaly is an AI platform for biomedical research that builds knowledge graphs and uses generative AI to surface evidence across scientific literature, drugs, and targets. It is the closest direct competitor to Epistemic AI's multi-agent biomedical intelligence proposition, serving similar biopharma R&D and strategy teams.
- Aitia (formerly Acorn AI): Aitia applies causal AI and multi-omics to drug discovery and development intelligence for biopharma. It overlaps with Epistemic AI in using AI to power pipeline, clinical, and commercial decision-making for pharma, though it leans more toward discovery-stage causal inference.
Broad incumbents
- Norstella (Citeline): Norstella, owner of Citeline and Pharma Intelligence, is the incumbent leader in pharma competitive intelligence, clinical trials data, and pipeline tracking. It is the default workflow against which Epistemic AI competes in Top-20 pharma strategy teams, though it embeds AI as a feature within a broader portfolio rather than as a standalone specialized product.
- IQVIA: IQVIA is the largest life sciences data, analytics, and services provider, spanning clinical trials, real-world evidence, and competitive intelligence. Its breadth of data assets and enterprise relationships make it a structural incumbent in the same buyer workflows Epistemic AI targets.
- Elsevier (Reaxys / Embase): Elsevier operates Reaxys, Embase, and Scopus, which are entrenched scientific and biomedical literature data sources frequently used by pharma strategy and competitive intelligence teams. As a publisher-data incumbent, it overlaps with the evidence base that powers Epistemic AI's deliverables.
- Veeva Systems: Veeva is the dominant cloud software platform for life sciences, spanning commercial, medical, regulatory, and R&D workflows. As biopharma customers consolidate AI features into Veeva and adjacent stacks, Veeva represents an indirect competitive threat to standalone intelligence platforms like Epistemic AI.
Emerging players
- Insilico Medicine: Insilico Medicine applies generative AI across target discovery, molecular design, and clinical trial prediction for biopharma. While primarily focused on drug discovery rather than strategic intelligence, it overlaps in the broader AI-for-life-sciences value proposition and competes for similar biopharma AI budget.
- BenevolentAI: BenevolentAI builds biomedical knowledge graphs combined with AI to identify novel drug targets and support clinical development decisions. It overlaps with Epistemic AI's graph-based approach and life sciences customer base, though it is more target-discovery oriented.
- Recursion Pharmaceuticals: Recursion combines high-throughput biology with AI/ML for drug discovery. While its primary focus is internal pipeline development rather than selling intelligence tools, its scale and AI-native positioning put it in the conversation when biopharma customers evaluate AI-for-R&D partners.
- Owkin: Owkin applies federated AI to biomedical and clinical data for biopharma R&D and clinical development. While more focused on real-world data and clinical research than strategic intelligence, it competes for similar AI-for-life-sciences budget and mind share with pharma enterprise buyers.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Epistemic AI social profiles
Digital presenceEpistemic AI financial estimates
Financial estimateRevenue estimate
Valuation estimate
Epistemic AI leadership team
Management profileNumber of profiles
Profiles12 records
Epistemic AI funding detail
Funding detailFunding overview
Funding rounds5 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Epistemic AI M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Epistemic AI
What does Epistemic AI do?
Epistemic AI sells a Strategic Intelligence Platform for Life Sciences built around EpistemicGPT, a multi-agent generative AI system grounded in a proprietary Epistemic Knowledge Graph of billions of biomedical entities. The platform automates competitive landscapes, target product profiles (TPPs), conference intelligence, clinical trials analysis, KOL mapping, drug and omics mapping for biopharma corporate strategy, portfolio planning, and medical affairs teams, with outputs validated by in-house life science experts.
Is Epistemic AI a public or private company?
Epistemic AI is a private company. It is classified as venture growth investor backed and is currently operating.
When was Epistemic AI founded?
Epistemic AI was founded in 2021. It employs 11 to 50 people.
Where is Epistemic AI based?
Epistemic AI is headquartered in Westport, United States, in the North America region.
How does Epistemic AI make money?
Two revenue lines are on record. Living Platform Subscription is the primary driver. The others are strategic Automation Projects.
Who are Epistemic AI's main competitors?
Direct peers on record are Causaly and Aitia (formerly Acorn AI). Broad incumbents are Norstella (Citeline), IQVIA, Elsevier (Reaxys / Embase) and Veeva Systems. Emerging players are Insilico Medicine, BenevolentAI, Recursion Pharmaceuticals and Owkin.
Does Epistemic AI have an API?
No public API is recorded for Epistemic AI.
What industry is Epistemic AI in?
Epistemic AI's product category is Life Sciences Strategic Intelligence Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HDAEANAA, End-to-End Enterprise AI Platforms (MLOps & Model Lifecycle Management). Its NAICS code is 51321 and its SIC code is 7372.